Last reviewed · How we verify
ALKS 8700
ALKS 8700 is a combination of aripiprazole monohydrate and flupenthixol decanoate designed to provide sustained antipsychotic activity through dopamine modulation.
ALKS 8700 is a combination of aripiprazole monohydrate and flupenthixol decanoate designed to provide sustained antipsychotic activity through dopamine modulation. Used for Schizophrenia, Bipolar I disorder.
At a glance
| Generic name | ALKS 8700 |
|---|---|
| Sponsor | Biogen |
| Drug class | Antipsychotic combination (long-acting injectable) |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
ALKS 8700 combines two antipsychotic agents: aripiprazole (a partial dopamine D2 receptor agonist) and flupenthixol decanoate (a typical antipsychotic with dopamine antagonist properties). The combination is formulated as a long-acting injectable to improve medication adherence and provide continuous antipsychotic coverage in patients with schizophrenia or bipolar disorder.
Approved indications
- Schizophrenia
- Bipolar I disorder
Common side effects
- Injection site reactions
- Akathisia
- Extrapyramidal symptoms
- Weight gain
- Sedation
Key clinical trials
- A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 (PHASE3)
- A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 (PHASE3)
- A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALKS 8700 CI brief — competitive landscape report
- ALKS 8700 updates RSS · CI watch RSS
- Biogen portfolio CI